Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | CASP3 | P42574 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119442 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL29908070 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL2309917 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL119451 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL29401991 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL30096349 | 0.92 | CASP3 (0.54) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL29391787 | 0.91 | MDM4 (0.51) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL27142935 | 0.91 | KMT2A (0.54) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL27142932 | 0.91 | KMT2A (0.54) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL20526769 | 0.90 | MDM4 (0.56) | MDM4TP53CASP3KMT2ASLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282826-A1 | PREPARATION METHOD, INTERMEDIATES, AND USE OF CYCLIC PEPTIDE TOXIN ALPHA-AMANITIN AND/OR AMANINAMIDE | INNER MONGOLIA UNIVERSITY (CN) | 2025-09-11 | — | — | US | claimed |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-06-26 | — | — | US | claimed |
| CN-119350469-B | Method for synthesizing CAGRILINTIDE by large fragment SPPS-LPPS mixing method | 杭州诺澳生物医药科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-118490852-B | Intracellular-constructed legumain-responded PET/MR bimodal molecular probe and application thereof | 安徽医科大学第一附属医院 | 2025-05-16 | — | — | CN | claimed |
| CN-118459541-B | Preparation method, intermediate and application of cyclopeptide toxin alpha-Amanitin and/or AMANINAMIDE | 内蒙古大学 | 2025-03-28 | — | — | CN | claimed |
| CN-118459547-B | Preparation method, intermediate and application of cyclopeptide toxin alpha-Amanitin and/or AMANINAMIDE | 内蒙古大学 | 2025-03-11 | — | — | CN | claimed |
| CN-118459546-B | Preparation method, intermediate and application of cyclopeptide toxin alpha-Amanitin and/or AMANINAMIDE | 内蒙古大学 | 2025-02-28 | — | — | CN | claimed |
| CN-119504503-A | Method for efficiently preparing Fmoc-Dap-OH | 成都市科隆化学品有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119391738-A | Method for improving soluble expression of recombinant N-acetylglucosamine transferase IVa | 北京柏因生物科技有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-119350469-A | Method for synthesizing CAGRILINTIDE by large fragment SPPS-LPPS mixing method | 杭州诺澳生物医药科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-115038711-A | Synthetic method of atosiban | 湖北健翔生物制药有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-114948850-A | Medicine-carrying oligopeptide and preparation method and application of soluble layered microneedle thereof | 中国药科大学 | 2022-08-30 | — | — | CN | claimed |
| CN-114805525-A | Preparation method of conopeptide | 深圳市健元医药科技有限公司 | 2022-07-29 | — | — | CN | claimed |
| WO-2022141615-A1 | SYNTHESIS METHOD FOR ATOSIBAN | 湖北健翔生物制药有限公司 | 2022-07-07 | — | — | WO | claimed |
| CN-114685614-A | Solid-phase synthesis method of atosiban | 湖北健翔生物制药有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-114685613-A | Preparation method of terlipressin impurity Q | 深圳翰宇药业股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-111534495-B | Method for improving soluble expression of recombinant N-acetylglucosamine transferase II | 江南大学 | 2022-06-17 | — | — | CN | claimed |
| CN-112175067-B | Preparation method of teduglutide | 深圳市星银医药有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-114315974-A | Synthetic method of procatide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-109180803-B | Somatostatin and preparation method and pharmaceutical composition thereof | 成都天台山制药有限公司 | 2022-02-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282826-A1 | PREPARATION METHOD, INTERMEDIATES, AND USE OF CYCLIC PEPTIDE TOXIN ALPHA-AMANITIN AND/OR AMANINAMIDE | VIP, PTMA, MLEC | MDM4 4560/4885TP53 2026/4885CASP3 1519/4885 |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | QPCT, SSTR5, SSTR4 | MDM4 1815/4885TP53 494/4885CASP3 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.